Literature DB >> 12959937

Activation of the CRF 2 receptor modulates skeletal muscle mass under physiological and pathological conditions.

Richard T Hinkle1, Elizabeth Donnelly, David B Cody, Steven Samuelsson, Jana S Lange, Mary Beth Bauer, Mark Tarnopolsky, Russell J Sheldon, Sarah C Coste, Eric Tobar, Mary P Stenzel-Poore, Robert J Isfort.   

Abstract

Two receptors activated by the corticotropin-releasing factor (CRF) family of peptides have been identified, the CRF 1 receptor (CRF1R) and the CRF 2 receptor (CRF2R). Of these, the CRF2R is expressed in skeletal muscle. To understand the role of the CRF2R in skeletal muscle, we utilized CRFR knockout mice and CRF2R-selective agonists to modulate nerve damage and corticosteroid- and disuse-induced skeletal muscle atrophy in mice. These analyses demonstrated that activation of the CRF2R decreased nerve damage and corticosteroid- and disuse-induced skeletal muscle mass and function loss. In addition, selective activation of the CRF2R increased nonatrophy skeletal muscle mass. Thus we describe for the first time a novel activity of the CRF2R, modulation of skeletal muscle mass.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12959937     DOI: 10.1152/ajpendo.00081.2003

Source DB:  PubMed          Journal:  Am J Physiol Endocrinol Metab        ISSN: 0193-1849            Impact factor:   4.310


  13 in total

1.  Corticotropin releasing factor 2 receptor agonists reduce the denervation-induced loss of rat skeletal muscle mass and force and increase non-atrophying skeletal muscle mass and force.

Authors:  R T Hinkle; E Donnelly; D B Cody; M B Bauer; R J Sheldon; R J Isfort
Journal:  J Muscle Res Cell Motil       Date:  2005-02-09       Impact factor: 2.698

2.  Topographical distribution of corticotropin-releasing factor type 2 receptor-like immunoreactivity in the rat dorsal raphe nucleus: co-localization with tryptophan hydroxylase.

Authors:  J L Lukkes; D R Staub; A Dietrich; W Truitt; A Neufeld-Cohen; A Chen; P L Johnson; A Shekhar; C A Lowry
Journal:  Neuroscience       Date:  2011-03-29       Impact factor: 3.590

Review 3.  cAMP signaling in skeletal muscle adaptation: hypertrophy, metabolism, and regeneration.

Authors:  Rebecca Berdeaux; Randi Stewart
Journal:  Am J Physiol Endocrinol Metab       Date:  2012-02-21       Impact factor: 4.310

4.  Loss of Unconventional Myosin VI Affects cAMP/PKA Signaling in Hindlimb Skeletal Muscle in an Age-Dependent Manner.

Authors:  Lilya Lehka; Dominika Wojton; Małgorzata Topolewska; Vira Chumak; Łukasz Majewski; Maria Jolanta Rędowicz
Journal:  Front Physiol       Date:  2022-06-28       Impact factor: 4.755

5.  Recovery of respiratory function in mdx mice co-treated with neutralizing interleukin-6 receptor antibodies and urocortin-2.

Authors:  David P Burns; Leonie Canavan; Jane Rowland; Robin O'Flaherty; Molly Brannock; Sarah E Drummond; Dervla O'Malley; Deirdre Edge; Ken D O'Halloran
Journal:  J Physiol       Date:  2018-10-03       Impact factor: 5.182

6.  Urocortin 3 transgenic mice exhibit a metabolically favourable phenotype resisting obesity and hyperglycaemia on a high-fat diet.

Authors:  P M Jamieson; M E Cleasby; Y Kuperman; N M Morton; P A T Kelly; D G Brownstein; K J Mustard; J M Vaughan; R N Carter; C N Hahn; D G Hardie; J R Seckl; A Chen; W W Vale
Journal:  Diabetologia       Date:  2011-06-11       Impact factor: 10.122

7.  Treatment with a corticotrophin releasing factor 2 receptor agonist modulates skeletal muscle mass and force production in aged and chronically ill animals.

Authors:  Richard T Hinkle; Frank R Lefever; Elizabeth T Dolan; Deborah L Reichart; Janice M Zwolshen; Timothy P Oneill; Kris G Maloney; John P Mattson; Leonardo F Ferreira; Timothy I Musch; David C Poole; Robert J Isfort
Journal:  BMC Musculoskelet Disord       Date:  2011-01-14       Impact factor: 2.362

8.  Activation of the dopamine 1 and dopamine 5 receptors increase skeletal muscle mass and force production under non-atrophying and atrophying conditions.

Authors:  Deborah L Reichart; Richard T Hinkle; Frank R Lefever; Elizabeth T Dolan; Jeffrey A Dietrich; David R Sibley; Robert J Isfort
Journal:  BMC Musculoskelet Disord       Date:  2011-01-26       Impact factor: 2.362

9.  Central urocortin 3 and type 2 corticotropin-releasing factor receptor in the regulation of energy homeostasis: critical involvement of the ventromedial hypothalamus.

Authors:  Peilin Chen; Christine Van Hover; Daniel Lindberg; Chien Li
Journal:  Front Endocrinol (Lausanne)       Date:  2013-01-07       Impact factor: 5.555

10.  Corticortophin releasing factor 2 receptor agonist treatment significantly slows disease progression in mdx mice.

Authors:  Richard T Hinkle; Frank R Lefever; Elizabeth T Dolan; Deborah L Reichart; Jefferey A Dietrich; Kathryn E Gropp; Robert I Thacker; Jeffrey P Demuth; Paula J Stevens; Xiaoyan A Qu; Alex R Varbanov; Feng Wang; Robert J Isfort
Journal:  BMC Med       Date:  2007-07-12       Impact factor: 8.775

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.